mpo dna Search Results


myeloperoxidase (mpo)-dna elisa  (CH Instruments)
90
CH Instruments myeloperoxidase (mpo)-dna elisa
Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated <t>myeloperoxidase</t> (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test
Myeloperoxidase (Mpo) Dna Elisa, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mpo+dna/pmc06478874-115-49-28?v=CH+Instruments
Average 90 stars, based on 1 article reviews
myeloperoxidase (mpo)-dna elisa - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
plasmid containing the human mpo dna segment from −1088 to −523  (TATAA Biocenter AB)
90
TATAA Biocenter AB plasmid containing the human mpo dna segment from −1088 to −523
Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated <t>myeloperoxidase</t> (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test
Plasmid Containing The Human Mpo Dna Segment From −1088 To −523, supplied by TATAA Biocenter AB, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mpo+dna/pm09001423-100-36-2?v=TATAA+Biocenter+AB
Average 90 stars, based on 1 article reviews
plasmid containing the human mpo dna segment from −1088 to −523 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mpo–dna complex levels measurement  (CSL Behring)
90
CSL Behring mpo–dna complex levels measurement
Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated <t>myeloperoxidase</t> (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test
Mpo–Dna Complex Levels Measurement, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mpo+dna/pmc08766396-207-3-22?v=CSL+Behring
Average 90 stars, based on 1 article reviews
mpo–dna complex levels measurement - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
biotin-labeled myeloperoxidase (mpo) dna  (Oncor Inc)
90
Oncor Inc biotin-labeled myeloperoxidase (mpo) dna
Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated <t>myeloperoxidase</t> (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test
Biotin Labeled Myeloperoxidase (Mpo) Dna, supplied by Oncor Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mpo+dna/291LWavI2LBePpuMzOOHtnfh5XP2tralGuUFTCNfooUKll2Nzwetlb6Vw0M44VHXw0kmU6bwqIezV-38-27-30?v=Oncor+Inc
Average 90 stars, based on 1 article reviews
biotin-labeled myeloperoxidase (mpo) dna - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
mpo dna levels  (Wolters Kluwer Health)
86
Wolters Kluwer Health mpo dna levels
Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated <t>myeloperoxidase</t> (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test
Mpo Dna Levels, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mpo+dna/10__1097_slash_01__hjh__0001196492__93400__22-83-0-12?v=Wolters+Kluwer+Health
Average 86 stars, based on 1 article reviews
mpo dna levels - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
mouse mpo dna elisa kit jingkang cat  (Shanghai Model Organisms Center)
86
Shanghai Model Organisms Center mouse mpo dna elisa kit jingkang cat
Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated <t>myeloperoxidase</t> (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test
Mouse Mpo Dna Elisa Kit Jingkang Cat, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mpo+dna/pm41075784-290-92-121?v=Shanghai+Model+Organisms+Center
Average 86 stars, based on 1 article reviews
mouse mpo dna elisa kit jingkang cat - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test

Journal: Nature Communications

Article Title: Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

doi: 10.1038/s41467-019-09801-x

Figure Lengend Snippet: Cyclic AMP (cAMP) suppresses NETosis in response to APS IgG. Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG (pooled from four patients with primary APS) for 3 h. Some samples were additionally treated with 8-Br-cAMP at various concentrations. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. 8-Br-cAMP = 1 µM, blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d Neutrophils were treated with either control IgG or APS IgG. Forskolin and PDE4 inhibitor were additionally added to some samples. NETosis was quantified by the enzymatic activity of nuclease-liberated MPO; * p < 0.05 and ** p < 0.01 by one-way ANOVA corrected with Sidak’s test

Article Snippet: Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model.

Techniques: Isolation, Control, Fluorescence, Activity Assay, Standard Deviation, Immunofluorescence, Microscopy

Agonism of the adenosine A 2A receptor suppresses NETosis. a , b Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG for 3 h. Some samples were additionally treated with agonists of the adenosine A 2A receptor (CGS21680), A 2B receptor (BAY60-6583), or A 3 receptor (IB-MECA) as indicated. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the APS IgG/no-drug group by one-way ANOVA corrected with Sidak’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. Blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d , e Neutrophils were treated with affinity-purified anti-β 2 GPI IgG (black bars) in the presence or absence of the A 2A receptor agonist. Extracellular DNA ( d ) or NETs ( e ) were quantified as above. Mean and standard deviation are presented for n = 3 independent experiments; ** p < 0.01 as compared with the no-drug group by one-way ANOVA corrected with Dunnett’s test. f Neutrophils were treated with APS IgG (black bars) in the presence of a protein kinase A inhibitor (PKAi) or an inhibitor of the exchange protein activated by cyclic-AMP pathway (EPACi) as indicated, and NETs were quantified. Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05

Journal: Nature Communications

Article Title: Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

doi: 10.1038/s41467-019-09801-x

Figure Lengend Snippet: Agonism of the adenosine A 2A receptor suppresses NETosis. a , b Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG for 3 h. Some samples were additionally treated with agonists of the adenosine A 2A receptor (CGS21680), A 2B receptor (BAY60-6583), or A 3 receptor (IB-MECA) as indicated. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 as compared with the APS IgG/no-drug group by one-way ANOVA corrected with Sidak’s test. c NETosis was assessed qualitatively by immunofluorescence microscopy. Blue = DNA, green = extracellular neutrophil elastase, and scale bar = 100 microns. d , e Neutrophils were treated with affinity-purified anti-β 2 GPI IgG (black bars) in the presence or absence of the A 2A receptor agonist. Extracellular DNA ( d ) or NETs ( e ) were quantified as above. Mean and standard deviation are presented for n = 3 independent experiments; ** p < 0.01 as compared with the no-drug group by one-way ANOVA corrected with Dunnett’s test. f Neutrophils were treated with APS IgG (black bars) in the presence of a protein kinase A inhibitor (PKAi) or an inhibitor of the exchange protein activated by cyclic-AMP pathway (EPACi) as indicated, and NETs were quantified. Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05

Article Snippet: Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model.

Techniques: Isolation, Control, Fluorescence, Activity Assay, Standard Deviation, Immunofluorescence, Microscopy, Affinity Purification

An adenosine A 2A receptor agonist suppresses reactive oxygen species (ROS). a , b Neutrophils were isolated from healthy volunteers and then treated with PMA for 3 h. Some samples were additionally treated with agonists of the adenosine A 2A receptor (CGS21680), A 2B receptor (BAY60-6583), or A 3 receptor (IB-MECA). In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; ** p < 0.01 as compared with the PMA/no-drug group by one-way ANOVA corrected with Dunnett’s test. c , d Neutrophils were treated with PMA, control IgG, or APS IgG in the presence or absence of the A 2A receptor agonist or 8-Br-cAMP for 1 h. Hydrogen peroxide formation was measured by a colorimetric assay. Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 and ** p < 0.01 as compared with the PMA-alone group ( c ) or APS-IgG-alone group ( d ) bye one-way ANOVA corrected with Dunnett’s test

Journal: Nature Communications

Article Title: Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

doi: 10.1038/s41467-019-09801-x

Figure Lengend Snippet: An adenosine A 2A receptor agonist suppresses reactive oxygen species (ROS). a , b Neutrophils were isolated from healthy volunteers and then treated with PMA for 3 h. Some samples were additionally treated with agonists of the adenosine A 2A receptor (CGS21680), A 2B receptor (BAY60-6583), or A 3 receptor (IB-MECA). In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; ** p < 0.01 as compared with the PMA/no-drug group by one-way ANOVA corrected with Dunnett’s test. c , d Neutrophils were treated with PMA, control IgG, or APS IgG in the presence or absence of the A 2A receptor agonist or 8-Br-cAMP for 1 h. Hydrogen peroxide formation was measured by a colorimetric assay. Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 and ** p < 0.01 as compared with the PMA-alone group ( c ) or APS-IgG-alone group ( d ) bye one-way ANOVA corrected with Dunnett’s test

Article Snippet: Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model.

Techniques: Isolation, Fluorescence, Activity Assay, Standard Deviation, Control, Colorimetric Assay

Dipyridamole suppresses NETosis via activation of the adenosine A 2A receptor. a , b Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG for 3 h. Some samples were additionally treated with dipyridamole as indicated. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05, ** p < 0.01, and *** p < 0.001 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c , d Neutrophils were treated with APS IgG in the presence of different combinations of dipyridamole and the A 2A receptor antagonist SCH58261. Extracellular DNA ( c ) or NETs ( d ) were quantified as above. Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 and ** p < 0.01 by one-way ANOVA. e Neutrophils were treated with APS IgG (black bars) and dipyridamole as indicated. Adenosine was quantified in culture supernatants. Mean and standard deviation are presented for n = 4 independent experiments; * p < 0.05 by one-way ANOVA corrected with Sidak’s test. f , g Neutrophils were isolated from patients with primary APS and immediately placed in culture. Some samples were additionally treated with drugs as indicated. Extracellular DNA ( f ) or NETs ( g ) were quantified as above. Mean and standard deviation are presented for n = 9 patients; ** p < 0.01 and *** p < 0.001 as compared with the no-drug group by one-way ANOVA corrected with Dunnett’s test

Journal: Nature Communications

Article Title: Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

doi: 10.1038/s41467-019-09801-x

Figure Lengend Snippet: Dipyridamole suppresses NETosis via activation of the adenosine A 2A receptor. a , b Neutrophils were isolated from healthy volunteers and then treated with either control IgG or APS IgG for 3 h. Some samples were additionally treated with dipyridamole as indicated. In panel a , total extracellular DNA was measured as relative fluorescence units upon the addition of Sytox Green. In panel b , an independent set of experiments was performed, with NETosis quantified by measuring the enzymatic activity of nuclease-liberated myeloperoxidase (MPO). Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05, ** p < 0.01, and *** p < 0.001 as compared with the 0 µM group by one-way ANOVA corrected with Dunnett’s test. c , d Neutrophils were treated with APS IgG in the presence of different combinations of dipyridamole and the A 2A receptor antagonist SCH58261. Extracellular DNA ( c ) or NETs ( d ) were quantified as above. Mean and standard deviation are presented for n = 3 independent experiments; * p < 0.05 and ** p < 0.01 by one-way ANOVA. e Neutrophils were treated with APS IgG (black bars) and dipyridamole as indicated. Adenosine was quantified in culture supernatants. Mean and standard deviation are presented for n = 4 independent experiments; * p < 0.05 by one-way ANOVA corrected with Sidak’s test. f , g Neutrophils were isolated from patients with primary APS and immediately placed in culture. Some samples were additionally treated with drugs as indicated. Extracellular DNA ( f ) or NETs ( g ) were quantified as above. Mean and standard deviation are presented for n = 9 patients; ** p < 0.01 and *** p < 0.001 as compared with the no-drug group by one-way ANOVA corrected with Dunnett’s test

Article Snippet: Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model.

Techniques: Activation Assay, Isolation, Control, Fluorescence, Activity Assay, Standard Deviation

Agonism of the adenosine A 2A receptor mitigates venous thrombosis in control mice. a Neutrophils were prepared from the bone marrow of C57BL/6 mice and then treated with control IgG or APS IgG. Some samples were additionally treated with CGS21680. NETosis was quantified by immunofluorescence microscopy. Mean and standard deviation are presented for n = 3 independent experiments; *** p < 0.001 by one-way ANOVA corrected with Sidak’s test. b Schematic of the flow-restriction model of venous thrombosis. The inferior vena cava is narrowed by fixing a ligature around the IVC (using a spacer, which is then removed). When a thrombus forms, it is just caudal to the stenosis in the area indicated by the spiral. Thrombus formation was assessed at 48 h for all of the following experiments. c – e Thrombus incidence ( c ), thrombus weight ( d ), and thrombus length ( e ) were assessed for C57BL/6 wild-type mice subjected to the flow-restriction model. Some mice were treated with the adenosine A 2A receptor agonist CGS21680 as indicated. Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model. Some mice were treated with dipyridamole as indicated; * p < 0.05 as compared with the control group (Chi-square test for panel g and unpaired t- test for panels h and i ). j Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group by unpaired t- test

Journal: Nature Communications

Article Title: Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

doi: 10.1038/s41467-019-09801-x

Figure Lengend Snippet: Agonism of the adenosine A 2A receptor mitigates venous thrombosis in control mice. a Neutrophils were prepared from the bone marrow of C57BL/6 mice and then treated with control IgG or APS IgG. Some samples were additionally treated with CGS21680. NETosis was quantified by immunofluorescence microscopy. Mean and standard deviation are presented for n = 3 independent experiments; *** p < 0.001 by one-way ANOVA corrected with Sidak’s test. b Schematic of the flow-restriction model of venous thrombosis. The inferior vena cava is narrowed by fixing a ligature around the IVC (using a spacer, which is then removed). When a thrombus forms, it is just caudal to the stenosis in the area indicated by the spiral. Thrombus formation was assessed at 48 h for all of the following experiments. c – e Thrombus incidence ( c ), thrombus weight ( d ), and thrombus length ( e ) were assessed for C57BL/6 wild-type mice subjected to the flow-restriction model. Some mice were treated with the adenosine A 2A receptor agonist CGS21680 as indicated. Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model. Some mice were treated with dipyridamole as indicated; * p < 0.05 as compared with the control group (Chi-square test for panel g and unpaired t- test for panels h and i ). j Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group by unpaired t- test

Article Snippet: Each data point represents a unique mouse, while horizontal lines denote mean values; * p < 0.05 and ** p < 0.01 as compared with the control group (Chi-square test for panel c and unpaired t- test for panels d and e ). f Plasma NETs were measured by myeloperoxidase (MPO)-DNA ELISA 48 h after flow restriction; * p < 0.05 as compared with the control group. g – i Thrombus incidence ( g ), thrombus weight ( h ), and thrombus length ( i ) were assessed for mice subjected to the flow-restriction model.

Techniques: Control, Immunofluorescence, Microscopy, Standard Deviation, Clinical Proteomics, Enzyme-linked Immunosorbent Assay